Evidence map›Paper›PMID 27106721›Full record

Trial reportDiabetologia2016

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.

Geraldine F Clough, Keith G McCormick, Eleonora Scorletti, Lokpal Bhatia, Philip C Calder, Michael J Griffin, Christopher D Byrne

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00760513 (The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease), which is not on this map. Cited by 7 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 5 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00760513 phase4completednot on this map

The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease

TypeinterventionalSponsorUniversity Hospital Southampton NHS Foundation TrustRan2009 to 2018Enrolled103ConditionsNon-Alcoholic Fatty Liver DiseaseArmsOMACOR, Placebo oral capsule
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Geraldine F CloughHuman Development and Health Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Keith G McCormickHuman Development and Health Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Eleonora ScorlettiHuman Development and Health Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Lokpal BhatiaHuman Development and Health Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Philip C CalderHuman Development and Health Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Michael J GriffinInstitute of Sound and Vibration Research, University of Southampton, Southampton, UK.
Christopher D ByrneHuman Development and Health Academic Unit, Faculty of Medicine, The Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK. cdtb@soton.ac.uk.
Southampton General Hospital · GBUniversity of Southampton · GBUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisThe effect of n-3 fatty acid treatment on temperature perception as a sensory nerve function modality is uncertain. In patients with non-alcoholic fatty liver disease (NAFLD) both with and without type 2 diabetes, we: (1) tested whether 15-18 months' treatment with 4 g/day of docosahexaenoic plus eicosapentaenoic acid (DHA+EPA) improved hot (HPT) and cold (CPT) temperature perception thresholds and (2) explored factors associated with HPT and CPT, in a randomised, double-blind, placebo-controlled trial.

methodsThe effect of treatment (n = 44) on HPT, CPT and temperature perception index (TPI: difference between HPT and CPT) was measured at the big toe in 90 individuals without neuropathy (type 2 diabetes; n = 30). Participants were randomised 1:1, using sequential numbering, by personnel independent from the trial team. All participants and all members of the research team were blinded to group assignment. Data were collected in the Southampton National Institute for Health Research Biomedical Research Centre. Treatment effects and the independence of associations were testing by regression modelling.

resultsMean ± SD age was 50.9 ± 10.6 years. In men (n = 53) and women (n = 37), HPTs (°C) were 46.1 ± 5.1 and 43.1 ± 6.4 (p = 0.02), CPTs (°C) were 22.7 ± 3.4 and 24.5 ± 3.6 (p = 0.07) and TPIs (°C) were 23.4 ± 7.4 and 18.7 ± 9.5 (p = 0.008), respectively. In univariate analyses, total body fat percentage (measured by dual-energy x-ray absorptiometry [DXA]) was associated with HPT (r = -0.36 p = 0.001), CPT (r = 0.35 p = 0.001) and TPI (r = 0.39 p = 0.0001). In multivariable-adjusted regression models, adjusting for age, sex and other potential confounders, only body fat percentage was independently associated with HPT, CPT or TPI (p = 0.006, p = 0.006 and p = 0.002, respectively). DHA+EPA treatment did not modify HPT, CPT or TPI (p = 0.93, p = 0.44 and p = 0.67, respectively). There were no important adverse effects or side effects reported. CONCLUSIONS/

interpretationHigher body fat percentage is associated with enhanced temperature perception. There was no benefit of treatment with high-dose n-3 fatty acids on the thresholds to detect hot or cold stimuli.

trial registrationClinicalTrials.gov NCT00760513

fundingThis work was supported by the National Institute for Health Research through the NIHR Southampton Biomedical Research Unit grant and by a Diabetes UK allied health research training fellowship awarded to KMcC (Diabetes UK. BDA 09/0003937).

Indexed as

TemperatureAdultCardiovascular SystemDiabetes Mellitus, Type 2Docosahexaenoic AcidsDouble-Blind MethodDrug CombinationsEicosapentaenoic AcidFatty LiverFemaleHumansInsulin ResistanceMaleMicrocirculationMiddle AgedNon-alcoholic Fatty Liver DiseaseDocosahexaenoic AcidsDrug CombinationsEicosapentaenoic AcidOmacorInsulin resistanceMicrocirculationn-3 Fatty acidNon-alcoholic fatty liver diseaseOmacor/LovazaSmall sensory nervesTemperature perception thresholdType 2 diabetes

Identifiers

PMID27106721
OpenAlexW2339942414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.